基本信息
views: 77
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Experienced pharmaceutical development and outcomes research professional, skilled in driving organic growth by converting innovative ideas to drug product based on disease burden, funding flows, and legislation landscape, with expertise in pharmaceutical R&D, regulatory affairs, and HEOR.
• Invented 2 nanomedicine platforms and secured $10M internal and external funding for 2 ongoing Phase I Clinical Trials
• Skilled in conducting HEOR with a focus on utilizing RWE for cost-effectiveness and budget impact analysis
• Led 5 FDA submissions (2 IND, 1 NDA, and 2 ANDA), and 2 Phase I Clinical Trials planning
• Broad knowledge in biology/pharmaceutical sciences principles, US healthcare ecosystem, and FDA compliance
• Proven track record of publication (36 peer-reviewed papers, Impact Factor > 300, total citation > 5000)
• Invented 2 nanomedicine platforms and secured $10M internal and external funding for 2 ongoing Phase I Clinical Trials
• Skilled in conducting HEOR with a focus on utilizing RWE for cost-effectiveness and budget impact analysis
• Led 5 FDA submissions (2 IND, 1 NDA, and 2 ANDA), and 2 Phase I Clinical Trials planning
• Broad knowledge in biology/pharmaceutical sciences principles, US healthcare ecosystem, and FDA compliance
• Proven track record of publication (36 peer-reviewed papers, Impact Factor > 300, total citation > 5000)
Research Interests
Papers共 42 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Current opinion in chemical biology (2021): 143-153
Cited0Views0Bibtex
0
0
MOLECULAR THERAPYno. 7 (2017): 1588-1595
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn